Lung cancer
  • Featured content
    In this CME-certified module with accompanying downloadable slideset, Todd M. Bauer, MD, provides expert insights on the biologic role of TRK fusions in cancer along with emerging clinical trial data on TRK-targeted therapies across multiple tumor types.
  • Featured content
    Expert faculty from the 2017-2018 CCO Local Live meeting series, “Expert Strategies to Optimize the Treatment of Patients With Squamous NSCLC,” answer frequently asked questions about treating squamous NSCLC, including considerations for newly diagnosed disease in special populations, choice of second-line immunotherapy, and management of immune-related adverse events.
  • Featured content
    Download this simple resource providing an overall summary of advanced NSCLC care including an up-to-date treatment algorithm, toxicity management, and a listing of key enrolling clinical trials.
    Date Posted: 2/15/2018
  • Featured content
    What is the best approach for our patients with progressive ALK-positive NSCLC? Here I share my thoughts based on the latest available evidence on using ALK inhibitors in the setting of progressive disease.
    Date Posted: 1/22/2018
  • Featured content
    Multiple biosimilars are now approved for the treatment of active cancers. Here’s what oncologists need to know.
    Date Posted: 1/18/2018
  • 1
  • 2
  • 3
  • 4
  • 5

Latest Content

10 of 237 Shown
10 of 237 Shown
Show 10 More